TAS-119 clinical trials
Also written VIC-1911 and TAS-119.
How each study uses TAS-119 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TAS-119 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 4
RenJi Hospital (2) · Taiho Oncology, Inc. (2) · Masonic Cancer Center, University of Minnesota (1) · Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. (1) · Vitrac Therapeutics, LLC (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses TAS-119 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung CancerRecruitingPhase 1Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.NCT05489731Written as VIC-1911How we know
- Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCCActive, not recruitingNot applicableRenJi HospitalNCT06519721Written as Lenvatinib Combined with VIC-1911How we know
- Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCCTerminatedNot applicableRenJi HospitalNCT05718882Written as Lenvatinib Oral Product Plus VIC1911How we know
- PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC TransplantationCompletedPhase 1/2Masonic Cancer Center, University of MinnesotaNCT05120570Written as VIC- 1911How we know
- VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung CancerTerminatedPhase 1Vitrac Therapeutics, LLCNCT05374538Written as VIC-1911How we know
- Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid TumorsTerminatedPhase 1Taiho Oncology, Inc.NCT02134067Written as TAS-119How we know
- An Investigation of TAS-119 MonotherapyTerminatedPhase 1Taiho Oncology, Inc.NCT02448589Written as TAS-119How we know
Codes
What other systems call TAS-119 · ClinicalTrials.gg INT001909
- MeSH (NLM) C000722916TAS-119One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722916 | TAS-119 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.